A single blind clinical study to evaluate the activity of Honasa Skin Renew Peptide Under Eye Cream for dark circle and ageing.
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
A single blind one arm study.
Each participant entering the trial will be assigned to a regimen of investigational product.
Day 0 (T0) - Baseline Measurements:
• Skin Hydration (Corneometer): Day 0, Day 1(for 24 hour check), Day 14)
• TEWL (Tewameter): (0 and 14 days)
• Skin Melanin(Mexameter): (0 and 14 days)
• Wrinkles (Visioface): ((0 and 14 days))
• Skin Firmness/Elasticity(Cutometer Assessment): (0 and 14 days)
• Dermatological Evaluations (5-Point Ordinal Scale,0-4): (0, 14days)
-
Dark circle severity Score ( Day 0 and Day 14)- with image
-
Eye puffiness Score ( Day 0 and Day 14)
-
Crow feet grading with Photonumeric Scale ( Day 0 and Day 14)- with image
• HD Imaging with DSLR: (0, 14 days)
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 25.00 Year(s) 至 45.00 Year(s)(—)
入选标准
- •Gender Male and Female aged between 25-
- •Non-pregnant, non-lactating female
- •Subject with crow feet and dark circle.
- •Subject willing to give written informed consent
- •Women of child bearing potential must have a negative urine pregnancy test.
- •Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE.
- •Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation, natural or artificial for the duration of the study.
排除标准
- •Subjects who are pregnant, breast feeding, or planning to become pregnant during the study
- •Volunteers with skin conditions such as eczema, psoriasis, etc
- •Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition.
- •Have open sore or open lesions in the treatment area
- •Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product.
- •Have participated in any interventional clinical trial in the previous 30 days.
- •Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents.
- •Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids.
- •Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.
研究者
Dr Robin Chugh
CCFT Laboratories
